natgillin/translations-raw huggingface dataset:
Use of a salt according to any of claims 1-8 in the preparation of a medicament for the treatment of a disease selected from the group consisting of Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and mania in bipolar disorder. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje bolesti izabrane iz skupine koja obuhvaća shizofreniju, shizofrenoformni poremećaj, shizoafektivni poremećaj, deluzije, kratki psihotični poremećaj, podijeljeni psihotični poremećaj i maniju kod bipolarnog poremećaja.
A method for manufacturing 4-((1R, 3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine (formula I) or a salt thereof, which method comprises conversion of the compound of formula Va in cis -configuration to the compound of formula I, wherein formula I and Va are as follows: 
Postupak proizvodnje 4-((1R,3S)-6-klor-3-fenilindan-1-il)-1,2,2-trimetilpiperazina (formula I) ili njegove soli, a postupak obuhvaća pretvorbu spoja formule Va cis-konfiguracije u spoj formule I, gdje su formula I i Va kako slijedi: [image]
The method of claim 15, comprising conversion of the alcohol group of the cis-alcohol of formula Va to a suitable leaving group LG resulting in the compound of formula VI. 
Postupak prema zahtjevu 15, obuhvaća pretvorbu alkoholne skupine cis-alkohola formule Va u odgovarajuću odlaznu skupinu LG što daje kao rezultat spoj formule VI. [image]
The method of claim 16 or 17, wherein Compound VI is precipitated from a suitable solvent. 
Postupak prema zahtjevu 16 ili 17, gdje se Spoj VI taloži iz odgovarajućeg otapala.
Compound VI is reacted with 2,2-dimethylpiperazine to obtain the compound of formula VII 
Spoj VI reagira s 2,2-dimetilpiperazinom radi dobivanja spoja formule VII [image]
Compound VII is methylated at the secondary amine to obtain the free base of the compound of formula I. 
Spoj VII je metiliran na sekundarnom aminu radi dobivanja slobodne baze spoja formule I.
The method of claim 21, wherein the formed salt is the hydrogen fumarate salt or the hydrogen maleate salt of Compound VII. 
Postupak prema zahtjevu 21, gdje je nastala sol vodik fumarat ili vodik maleat Spoja VII.
reacting Compound VI with 1-protected 2,2-dimethylpiperazine (IX), wherein PG is a protection group, thereby obtaining a compound of formula X; and 
reakciju Spoja VI s 1-zaštićenim 2,2-dimetilpiperazinom (IX), gdje je PG zaštitna skupina, čime se dobiva spoj formule X; i
Compound VI for which LG is Cl) with 2,2-dimethylpiperazine thereby obtaining the compound of formula VII, followed by methylation at the secondary amine. 
Spoja VI kojemu je odlazna skupina Cl) s 2,2-dimetilpiperazinom čime se dobiva spoj formule VII, nakon čega slijedi metilacija na sekundarnom aminu.
A method for manufacturing 4-((1R, 3S)-(6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine (formula I) or a salt thereof, which method comprises conversion of the compound of formula VII to the compound of formula I, wherein formula VII is as defined in claim 20. 
Postupak proizvodnje 4-((1R,3S)-(6-klor-3-fenilindan-1-il)-1,2,2-trimetilpiperazina (formula I) ili njegove soli, postupak obuhvaća pretvorbu spoja formule VII u spoj formule I, gdje je formula VII kao prema zahtjevu 20.
a salt of an organic acid, such as an organic diacid, in order to remove undesired cis diastereoisomer. 
sol organske kiseline, kao organske dikiseline, radi uklanjanja neželjenog cis diastereoizomera.
The method of claim 29, wherein the formed salt is a hydrogen fumarate salt of Compound I. 
Postupak prema zahtjevu 29, gdje je dobivena sol vodik fumarat sol Spoja I.
The method of claim 31, wherein the Compound I hydrogen succinate is prepared in a ketone solvent, preferably acetone, e.g. 
Postupak prema zahtjevu 31, gdje se vodik sukcinat spoja I priprema u ketonskom otapalu, poželjno acetonu, npr.
The method of claim 33, wherein the Compound I hydrogen malonate is prepared in a in a alcohol solvent, e.g. 
Postupak prema zahtjevu 33, gdje se vodik malonat spoja I priprema u alkoholnom otapalu, npr.
The method of any of claims 15-35 followed by isolation of the compound of formula I as the free base or as a salt thereof, e.g. 
Postupak prema bilo kojem od zahtjeva 15-35 nakon čega slijedi izolacija spoja formule I kao slobodne baze ili njegove soli, npr.
A compound (Va) having the structure: 
Spoj (Va) sa strukturom:
A foaming composition according to 4, wherein said fats comprise, on a dry weight basis of all fatty acids, between 30 and 80% of C12 and C14 fatty acids. 
Pjenušavi pripravak u skladu s 4, naznačen time što navedene masti čine, prema težini suhe tvari svih masnih kiselina, između 30 i 80% masnih kiselina C12 i C14.
introducing a gas in the mixture and drying. 
– uvođenju plina u smjesu i – sušenju.
A process according to claim 10, wherein at least a part of said proteins are introduced in said mixing step in a liquid form having a dry solids content of 20-55 % (w/w). 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što se u najmanju ruku dio navedenih proteina uvodi u navedenom koraku miješanja u obliku tekućine čiji je sadržaj suhih krutina od 20 do 55 % (tež./tež.).
A process according to claim 12, wherein the vegetable and/or animal extract or powder is selected from coffee extract, cocoa powder, tea extract and savoury powders. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se ekstrakt ili prah biljnog i/ili životinjskog podrijetla bira između ekstrakta kave, kakaa u prahu, čajnog ekstrakta i aroma u prahu.
Use of claim 4 in the preparation of a medicament for the treatment of schizophrenia or other psychotic disorders. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje shizofrenije ili drugih psihotičnih poremećaja.
an oral or parenteral dosage form containing a therapeutically effective amount of a solid ferric pyrophosphate citrate chelate composition having 2% or less phosphate by weight. 
Farmaceutska smjesa koja sadrži oralni ili parenteralni dozirni oblik koji sadrži terapijski učinkovitu količinu čvrste smjese kelata feri-pirofosfat citrata s 2% ili manje fosfata, težinski.
Pipeline pressure device according to one of the preceding claims, wherein the endless conveyor members and drive are configured for together exerting a thrust on the conveyor pipeline of at least 500 kN. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da su beskonačni transportni članovi (5) i pogon konfigurirani za zajedničko stvaranje potiska A na transportni cjevovod (6) od najmanje 500 kN.
A compound as claimed in claim 1, for the treatment of asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, or allergic rhinobronchitis. 
Spoj prema bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju astme, kronične opstruktivne plućne bolesti, rinitisa, sindroma alergije dišnih putova ili alergijskog rinobronhitisa.
A stone or marble slab border polishing machine comprising: 
Stroj za poliranje ruba kamene ili mramorne ploče, koji obuhvaća:
Polishing machine, as claimed in the preceding claim, characterized in that the lower part of the template (1) is orthogonal to the direction of feed of the slab (4) and forms a base or bracket (5) which is provided with coupling means which permit the coupling with the supporting frame (6) of the slab border polishing machine in the feed sector of the slab itself. 
Stroj za poliranje prema prethodnom zahtjevu, naznačen time, da je donji dio šablone (1) ortogonalan na smjer ulaska ploče (4) i oblikuje bazu ili podupirač (5) koji je opremljen sredstvima za spajanje koja dozvoljavaju spregu s nosivim okvirom (6) stroja za poliranje rubova ploča u području ulaska same ploče.
Polishing machine, as claimed in the preceding claims, characterized in that the template may be carried out with a supporting bracket (5) which is carried out as a separate piece and is provided with adjusting means such as slots (12); on the one hand, the slots (12) permit the template body to be fixed and on the other hand, the slots (12) permit the bracket to be fixed to the machine with fixing and adjusting means in which screws are utilized. 
Stroj za poliranje prema prethodnim zahtjevima, naznačen time, da se šablona može izvoditi s nosivim podupiračem (5) koji se izrađuje kao zaseban komad i opskrbljen je sredstvima za podešavanje kao što su prorezi (12); pri čemu s jedne strane, prorezi (12) dozvoljavaju da se tijelo šablone učvrsti, a s druge strane, prorezi (12) dozvoljavaju podupiraču da se učvrsti na stroj pomoću sredstava za učvršćivanje i podešavanje, gdje se koriste vijci.
Polishing machine, as claimed in the preceding claims, characterized in that there is a roll (13) which makes the sliding of the slab easier during the slab feeding on the conveyor belt. 
Stroj za poliranje prema prethodnim zahtjevima, naznačen time, da postoji valjak (13) koji olakšava klizanje ploče prilikom ulaženja ploče na transportnu traku.
An antigen-binding molecule capable of binding to PIGF, characterized in that it comprises the CDR regions corresponding to the sequences of SEQ ID NO: 17 to 22. 
Molekula koji veže antigen sposoban da veže PlGF, naznačena time, da sadrži CDR područja koja odgovaraju sekvencama SEQ ID NO: 17 do 22.
The antigen-binding molecule according to claim 1, which is a molecule selected from the group of Fab, Fab' or F(ab')2, a combination of at least two complementarity determining regions (CDRs), a soluble or membrane-anchored single-chain variable part, or single variable domain. 
Molekula koja veže antigen prema zahtjevu 1, naznačena time, da je navedena molekula odabrana iz skupine koja sadrži Fab, Fab' ili F(ab')2, kombinacije barem dva područja koja određuju komplementarnost (CDR), jedno-lančanog varijabilnog područja koje je spojeno na membranu ili pojedinačnu varijabilnu domenu.
The antigen-binding molecule of claim 1, which is a single-chain variable fragment. 
Molekula koja veže antigen prema zahtjevu 1, naznačena time, da navedena molekula predstavlja jedno-lančani varijabilni fragment.
selecting a PIGF-binding molecule capable of binding to the same PIGF epitope as antibody 16D3 based on reactivity with said epitope or based on competition with antibody 16D3. 
odabira molekule koja veže PlGF, a koja je sposobna vezati isti PlGF epitop kao i protutijelo 16D3 bazirano na reakciji sa navedenim epitopom ili bazirano na ogledu sa protutijelom 16D3.
The antigen-binding molecule or polynucleotide according to claim 18, wherein the pathological condition is selected from the group consisting of cancer, inflammation, adhesion formation, diseases of the eye, pulmonary hypertension and vascular leakage. 
Molekula koja veže antigen ili polinukleotid prema zahtjevu 18, naznačeni time, da je navedeno patološko stanje odabrano iz skupine koja sadrži rak, upalu, nastanak adhezije, bolesti oka, plućnu hipertenziju i propusnost stijenki krvnih žila.
The process according to claim 8, wherein the eluting solvent is a mixture of heptane and ethylacetate. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što je elucijsko otapalo smjesa heptana i etil-acetata.
The process according to claim 10, wherein said secosteroid is an analogue of vitamin D of formula (III): 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što je navedeni sekosteroid analog vitamina D, formule (III):
The process according to claim 10 or 11, wherein said secosteroid is inecalcitol of formula: 
Postupak u skladu s patentnim zahtjevom 10 ili 11, naznačen time što je navedeni sekosteroid inekalcitol formule:
The process according to claim 10, 11 or 12 further comprising the steps of: 
Postupak u skladu s patentnim zahtjevom 10, 11 ili 12, naznačen time što se dodatno sastoji u koracima:
said base (8) being fitted with a fan (9) designed to direct air onto the product in the cartridge and then into the room; 
na spomenutom podnožju (8) montiran je ventilator (9) koji usmjerava zrak na proizvod u patroni, i potom u prostoriju;
Diffuser as claimed in claim 1, characterised in that said flange (6) presents side openings (14) for suction of air to be directed towards the perfuming product. 
Raspršivač prema 1. zahtjevu, naznačen time da spomenuti izbočeni porub (6) ima bočne otvore (14) za usisavanje zraka koji se usmjerava prema mirisnom proizvodu.
Diffuser as claimed in claim 1, characterised in that the base (8) of said frame is fitted with an electronic card on which are mounted electronic devices designed to allow the local or remote management and control of the device. 
Raspršivač prema 1. zahtjevu, naznačen time da je podnožje (8) spomenutog okvira opremljeno elektroničkom karticom na koju su montirani elektronički uređaji koji omogućavaju lokalno ili daljinsko upravljanje i regulaciju uređaja.
Use according to claim 11, wherein the neurodegenerative disease is Alzheimer's Disease, in particular late-onset Alzheimer's Disease. 
Uporaba prema zahtjevu 11, naznačena time da je neurodegenerativna bolest Alzheimerova bolest, naročito Alzheimerova bolest s kasnim početkom.
Composition according to claim 14, wherein the dosage form is in particular in form of tablets or in sugar-cube type form or wherein a dose comprises a plurality of small tablets or capsules. 
Pripravak prema zahtjevu 14, naznačen time da je oblik doziranja naročito u obliku tableta ili u obliku šećerne kocke ili gdje doza sadrži veći broj malih tableta ili kapsula.
A compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein the carbon marked by an asterisk may have an (R) or an (S) configuration; and wherein R1 and R2 are fluoro, for use in a method for inhibiting cytidine deaminase (CDA). 
Spoj Formule I, ili njegova farmaceutski prihvatljiva sol: [image] gdje ugljik označen zvjezdicom može imati (R) ili (S) konfiguraciju; i gdje su R1 i R2 fluor.
The compound of claim 1 or 2, wherein the compound is represented by Compound 1a: 
Farmaceutska smjesa prema zahtjevu 4, gdje je spoj predstavljen kao Spoj 1a:
The kit of claim 5, further comprising a second compound which is a CDA substrate drug selected from the group consisting of 5-azacytidine, gemcitabine, ara-C, tezacitabine, 5-fluoro-2'-deoxycytidine, and cytochlor. 
lijek koji je supstrat za CDA, izabran iz skupine koja obuhvaća 5-azacitidin, gemcitabin, ara-C, tezacitabin, 5-fluoro-2’ -deoksicitidin i citoklor. Smjesa koja sadrži:
Suction tube device according to claim 1, wherein a drive system (11, 27) comprises a transmission (23). 
Uređaj koji ima cijev za usisavanje u skladu s patentnim zahtjevom 1, naznačen time što pogonski sustav (11, 27) ima uređaj za prijenos snage (23).
Suction tube device (2) according to any of claims 1-3, wherein the centrifugal pump drive system (27) comprises at least one torque limiting coupling arranged to protect the electric motor(s) from the centrifugal pump (16) in case of emergency. 
Uređaj koji ima cijev za usisavanje (2) u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što pogonski sustav (27) centrifugalne pumpe ima najmanje jednu spojku za ograničavanje okretnog momenta koja je postavljena tako da ona u slučaju potrebe štiti elektromotor/elektromotore u odnosu na centrifugalnu pumpu (16).
Use of compounds according to Claim 5-7, and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, neuropathy and/or nephropathy. 
Uporaba spojeva prema zahtjevu 5-7, i njihovih farmaceutski upotrebljivih soli i stereoizomera, uključujući njihove smjese u svim omjerima, naznačena time da je za dobivanje lijeka za liječenje bolesti ili stanja, gdje je bolest ili stanje dijabetes koji je ovisan o inzulinu, dijabetes koji nije ovisan o inzulinu, pretilost, neuropatija i/ili nefropatija.
Set (kit) consisting of separate packs of 
Kit (komplet) naznačen time da sadrži odvojena pakiranja
an effective amount of a further medicament active ingredient. 
učinkovite količine dodatnog aktivnog sastojka lijeka.
The use according to claim 1, wherein the refrigerant composition comprises 36 to 42 mass% of 1,1,1,2-tetrafluoroethane (HFC134a) and 58 to 64 mass% of 2,3,3,3-tetrafluoropropene (HFO1234yf). 
Rashladni sastav prema zahtjevu 1, naznačen time, da sadrži 36 do 42 masenih postotaka 1,1,1,2-tetrafluoroetana (HFC134a) i 58 do 64 masenih postotaka 2,3,3,3-tetrafluoropropana (HFO1234yf).
A compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein the carbon marked by an asterisk may have an (R) or an (S) configuration; and wherein R1 and R2 are fluoro, for use in a method for inhibiting degradation of a CDA substrate drug by CDA. 
Farmaceutska smjesa za inhibiciju aktivnosti enzima CDA koja uglavnom sadrži spoj Formule I, ili njegovu farmaceutski prihvatljivu sol: [image] gdje ugljik označen zvjezdicom može imati (R) ili (S) konfiguraciju; i gdje su R1 i R2 fluor; i farmaceutski prihvatljivu pomoćnu tvar.
A pharmaceutical composition comprising as active ingredient a compound according to any one of Claims 1-3, optionally together with a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, naznačen time, da kao aktivni sastojak obuhvaća spoj prema bilo kojem od zahtjeva 1 do 5, ili njegove stereoizomere ili njegove farmaceutski prihvatljive soli, zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem.
A compound according to any one of claims 1 to 5 or stereoisomers or pharmaceutically acceptable salts thereof in combination with an anti-inflammatory, bronchodilatory, anti-histamine or anti-tussive drug substance, said compound and said drug substance being in the same or different pharmaceutical composition. 
Spoj prema bilo kojem od zahtjeva 1 do 5, ili njegovi stereoizomeri ili njegove farmaceutski prihvatljive soli, naznačen time, da se upotrebljava u kombinaciji s s anti-upalnom, bronhodilatornom, anti-histaminskom ili anti-tusivnom ljekovitom tvari, pri čemu su spomenuti spoj i spomenuta ljekovita tvar u istom ili u različitom farmaceutskom sastavu.
A pharmaceutical composition comprising as active ingredient a compound according to any one of claims 1 to 5 or stereoisomers or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, naznačen time, da kao aktivni sastojak obuhvaća spoj prema bilo kojem od zahtjeva 1 do 5, ili njegove stereoizomere ili njegove farmaceutski prihvatljive soli, zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem.
providing a plurality of conduits (108) for receiving the fresh water, the conduits of the plurality being helically wrapped together in a parallel relationship along at least a portion of the length of the center tube (102), each of the plurality of conduits (108) being in contact with the center tube (102) to permit heat transfer therebetween; 
postavljanje niza cjevčica (108) za primanje svježe vode, više cjevčica je spiralno omotano zajedno u paralelnom odnosu duž barem dijela dužine središnje cijevi (102), svaka od više cjevčica (108) u doticaju je sa središnjom cijevi (102) kako bi se omogućio prijenos topline među njima;
causing the drain water to flow through the center tube (102) to thereby cause heat from the drain water to be transferred to the plurality of conduits (108) via the center tube (102); and causing the fresh water to flow through the plurality of conduits (108) to thereby heat the fresh water. 
tjeranje da drenažna voda protječe kroz središnju cijev (102) čime dolazi do prijenosa topline iz drenažne vode u niz cjevčica (108) preko središnje cijevi (102); i tjeranje da svježa voda protječe kroz niz cjevčica (108) koje će zagrijati svježu vodu. Postupak prema zahtjevu 1 gdje:
A fan assembly as claimed in claim 2. wherein the second member (300) is pivotably connected to the first member (304), 
Ventilatorski sustav prema zahtjevu 2. gdje je drugi član (300) pivotalno spojen na prvi član (304).
A fan assembly as claimed in claim 2 or claim 3, wherein the first member (304) comprises on air pipe for receiving the air flow. 
Ventilatorski sustav prema zahtjevu 2 ili zahtjevu 3, gdje prvi član (304) ima zračnu cijev za primanje struje zraka.
A fan assembly as claimed in claim 5, wherein the duet (18) is telescopic. 
Ventilatorski sustav prema zahtjevu 5, gdje je stalak (18) teleskopski.
A fan assembly as claimed in claim 7, wherein the means for creating an air flow comprises an impeller (64), motor (68) for rotating the impeller, and a diffuser (74) located downstream from the impeller (64). 
Ventilatorski sustav prema zahtjevu 7, gdje sredstva za stvaranje struje zraka obuhvaćaju propeler (64), motor (68) za okretanje propelera, i difuzor (74) koji se nalazi nakon propelera (64).
A fan assembly as claimed in claim 8. comprising means (122, 126) for guiding the air flow emitted from the diffuser (74) into the duct (18). 
Ventilatorski sustav prema zahtjevu 8 koji obuhvaća sredstva (122, 126) za vođenje struje zraka emitirane iz difuzora (74) u vod (18).
A fan assembly as claimed in claim 12, wherein the inner casing section (202) defines and extends about an opening (38) through which air from outside the fan assembly is drawn by the air flow emitted from the mouth (40). 
Ventilatorski sustav prema zahtjevu 12, gdje unutarnji dio kućišta (202) definira i pruža se oko otvora (38) kroz koji zrak izvan ventilatorskog sustava uvlači struja zraka emitirana iz usta (40).
A fan assembly as claimed in claim 13, wherein the opening (38) extends about the axis (X), and wherein the axis (X) is preferably substantially horizontal when the air outlet (14) is in an untilted position. 
Ventilatorski sustav prema zahtjevu 13, gdje se otvor (38) pruža oko osi (X), i gdje je os (X) poželjno u biti horizontalna kada je izlaz zraka (14) u nenagnutom položaju.
A fan assembly as claimed in claim 14, wherein axis (X) is inclined by an angle in the range from 5 to 15° when the air outlet (14) is moved from an untitled position to a fully tilted position. 
Ventilatorski sustav prema zahtjevu 14, gdje je os (X) nagnuta za kut u rasponu od 5 do 15° kada se izlaz zraka (14) pomakne iz nenagnutog položaja u potpuno nagnuti položaj.
A fan assembly as claimed in any of claims 12 to 15, wherein the inner casing section (202) and the outer casing section (200) define an interior passage (204) for receiving the air flow. 
Ventilatorski sustav prema bilo kojem zahtjevu 12 do 15, gdje unutarnji dio kućišta (202) i vanjski dio kućišta (200) definiraju unutarnji prolaz (204) za primanje struje zraka.
A fan assembly as claimed in claim 16, wherein the interior passage (204) is shaped to divide the received air flow into two air streams each flowing along a respective side of the opening (38). 
Ventilatorski sustav prema zahtjevu 16, gdje je unutarnji prolaz (204) oblikovan tako da dijeli primljenu struju zraka u dvije struje od kojih svaka ide duž odgovarajuće strane otvora (38).
A fan assembly as claimed in claim 16 or claim 17; wherein the interior passage (204) is substantially annular. 
Ventilatorski sustav prema zahtjevu 16 ili zahtjevu 17; gdje je unutarnji prolaz (204) u biti prstenast.
A fan assembly as claimed in any of claims 12 to 18, wherein the air outlet (14) comprises a surface (42) located adjacent the mouth (40) and over which the mouth (40) is arranged to direct the air flow. 
Ventilatorski sustav prema bilo kojem zahtjevu 12 do 18, gdje izlaz zraka (14) iam površinu (42) smještenu uz usta (40) i preko koje su usta (40) smještena da usmjeravaju struju zraka.
A fan assembly as claimed in claim 20, wherein the Coanda surface (42) extends about the opening (38). 
Ventilatorski sustav prema zahtjevu 20, gdje se Coanda površina (42) pruža oko otvora (38).
A fan assembly as claimed in claim 20 or claim 21, wherein the air outlet comprises a diffuser (44) located downstream of the Coanda surface (42). 
Ventilatorski sustav prema zahtjevu 20 ili zahtjevu 21, gdje izlaz zraka ima difuzor (44) koji dolazi nakon Coanda površine (42).
a fixed external structure (13), 
fiksnu vanjsku strukturu (13),